ClinicalTrials.Veeva

Menu
B

Bradenton Research Center | Bradenton, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bapineuzumab
YKP3089
Gantenerumab
Crenezumab
AVP-786
Rufinamide
Lyrica
Aducanumab
Eslicarbazepine Acetate
Donanemab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 66 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized...

Enrolling
Myasthenia Gravis, Generalized
Drug: DNTH103
Drug: Placebo

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling
Sjögren's Syndrome (SS)
Drug: Dazodalibep
Drug: Placebo

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug
Locations recently updated

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling
Sjogren's Syndrome
Drug: Dazodalibep
Drug: Placebo

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Active, not recruiting
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Invitation-only
Early Alzheimer's Disease
Drug: Experimental: ALZ-801

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Re...

Enrolling
Multiple Sclerosis
Drug: IMU-838 tablets
Drug: Placebo matching IMU-838 tablets

Trial sponsors

Pfizer logo
Roche logo
Eisai logo
Amgen logo
Genentech logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Otsuka logo
SK Life Science logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems